Venous thromboembolism: why does ethnicity matter?

BOUNAMEAUX, Henri, ROSENDAAL, Frits R


DOI : 10.1161/CIRCULATIONAHA.111.031690
PMID : 21555708
Venous Thromboembolism: Why Does Ethnicity Matter?
Henri Bounameaux and Frits R. Rosendaal

Circulation 2011;123;2189-2191; originally published online May 9, 2011;
DOI: 10.1161/CIRCULATIONAHA.111.031690

Circulation is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/cgi/content/full/123/20/2189

Subscriptions: Information about subscribing to Circulation is online at http://circ.ahajournals.org/subscriptions/
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050, Fax: 410-528-8550, E-mail: journalpermissions@lww.com
Reprints: Information about reprints can be found online at http://www.lww.com/reprints
Venous Thromboembolism
Why Does Ethnicity Matter?

Henri Bounameaux, MD; Frits R. Rosendaal, MD, PhD

Venous thromboembolism (VTE) is a disease that is caused by genetic and environmental factors that interact in a dynamic, time-dependent model.1 Therefore, it is not astonishing that, although VTE is seen throughout the world, the rate of its clinical manifestations, deep venous thrombosis (DVT) and pulmonary embolism (PE), varies. Thus, Asian and Native American individuals have been reported to have a significantly lower rate of VTE than whites and blacks; the latter present with the highest rate2 and worst 90-day prognosis.3

The table displays the incidence rates of VTE and fatal PE and age-at-death in fatal PE as well as the prevalence of the factor V Leiden and prothrombin 20210A mutations according to ethnicity, based on the literature and on the report by Tang et al. In aggregate, these figures reveal not only a few consistent facts, but also some intriguing clues. Compared with nonblacks, blacks experience 40% more VTE and 3 times more frequent fatal PE and die at a 10-year younger age in the case of fatal PE, but they do not carry the factor V Leiden and prothrombin 20210A mutations. It is noteworthy that the Leiden mutation was strongly associated with earlier age-at-death from PE. As expected, however, the 2 previously mentioned mutations were very rare or absent among nonwhites. The authors also report data on the molecular testing of the methylenetetrahydrofolate reductase C677T variant, which is not, however, a prothrombotic factor. From a clinical perspective, there is no point at all in measuring it, and indeed it did not stand out in this study.

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the Division of Angiology and Hemostasis, University Hospitals and Faculty of Medicine of Geneva, Switzerland (H.B.); and the Departments of Clinical Epidemiology and of Thrombosis and Hemostasis, Leiden University Medical Center, the Netherlands (F.R.R.).

Correspondence to H. Bounameaux, MD, Division of Angiology and Hemostasis, Hôpitaux Universitaires de Genève, 4, rue Gabrielle-Perret-Gentil, CH-1211 Geneva 14, Switzerland. E-mail henri.bounameaux@unige.ch

(Circulation. 2011;123:2189-2191.)
© 2011 American Heart Association, Inc.

Circulation is available at http://circ.ahajournals.org
DOI: 10.1161/CIRCULATIONAHA.111.031690
of 9 years of age at death will, at least in part, be explained by this age difference in the 2 populations.

There are several other potential limitations to the data presented, starting from the definition of ethnic groups, especially in the United States, where mixed ethnic backgrounds are not uncommon. In addition, the methodological quality of the epidemiological studies in the field is far from ideal. In the report by Tang et al, the focus is on the end point of fatal PE, which implies that we observe the tip of the iceberg, and 2 denominators are missing: first, there is a population with a distribution of risk factors, from which, second, originate cases with PE, of whom some subsequently die. When focusing on the last group, and comparing results with the general population, results should be interpreted with caution. For instance, factor V Leiden genotypes are higher among those with fatal PE than in the general population, but this does not imply that factor V Leiden specifically increases the risk of embolic death; it is a risk factor for PE, and so increased in those with all forms of VTE (the second denominator). Similarly, when factor V Leiden prevalence among white and black PE deaths are compared, they are different because they differ in the 2 denominators: in the population as a whole, there is a racial difference in factor V Leiden prevalence, whereas in PE patients (the population at risk to die of PE), there are more carriers of the Leiden mutation than in the population as a whole, because it is a risk factor for PE. When one only looks at the fatal cases, one cannot see in which of the 2 denominators the difference actually occurs, and whether a factor increases risk of all PE, or specifically fatal PE.

Nevertheless, these observations point to the large disparity of clinical presentation of VTE, ranging from isolated DVT to extensive proximal DVT with or without PE, isolated PE, and fatal PE. It also suggests that these clinical presentations might not just occur by chance as one type or the other, which is further supported by the fact that patients who have a recurrence after a DVT often again have DVT, whereas patients who experienced a PE often experience recurrence of a PE. This leads us to postulate yet unrecognized genetic predispositions to the one clinical type or the other. If this were true, blacks would have a particular predisposition to VTE, and specifically to PE, causing death at an early age, possibly in relation with a particular thrombus composition that makes it less stable, less attached to the vessel wall, and more prone to embolize. It is certain that the last word has not been said about this, and genetic breakthroughs in the future will provide new insight into a disease that may prove less simple than most clinicians believe.

But before this happens, what should be done based on our present knowledge? First, thoroughly designed epidemiological research should focus on nonwhite populations to identify genetic and other risk factors for VTE, especially fatal PE. Second, public policies such as outlined in the recent Surgeon General’s call should particularly target ethnic groups that are at higher risk. Third, clinicians should integrate the higher risk of VTE in blacks in their clinical assessment in patients clinically suspected of DVT or PE, and monitor treatment with utmost care in these patients once diagnosis has been confirmed.

**Disclosures**

None.

**References**


**Keywords:** ethnic groups ■ mortality ■ pulmonary embolism ■ thrombophilia ■ venous thromboembolism